Research progress in C-reactive protein and the prognosis of immunotherapy for non-small cell lung cancer
10.3760/cma.j.cn371439-20240805-00133
- VernacularTitle:C-反应蛋白与非小细胞肺癌免疫治疗预后的研究进展
- Author:
Caihong FU
1
;
Yuanchun XIN
;
Feng GU
;
Yuqiang WU
;
Huihui LI
;
Qin MA
;
Xiting LIU
;
Lei YANG
Author Information
1. 甘肃省肿瘤医院呼吸肿瘤内科，兰州 730000
- Keywords:
Carcinoma, non-small cell lung;
C-reactive protein;
Immunotherapy;
Prognosis
- From:
Journal of International Oncology
2024;51(12):785-788
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has become the first-line standard treatment option for driver gene-negative advanced non-small cell lung cancer (NSCLC). But not all patients can benefit from immunotherapy, and can even have serious adverse reactions. It is crucial to identify the predictors of clinical response to immunotherapy. Several studies have shown that elevated baseline C-reactive protein (CRP) or persistent elevation of CRP during the treatment process may indicate a poorer prognosis for patients, and high CRP may be correlated with adverse reactions. Attention to the dynamic changes of CRP during immunotherapy for NSCLC may become an important predictor of prognosis.
